ZA200802874B - Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases - Google Patents

Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases

Info

Publication number
ZA200802874B
ZA200802874B ZA200802874A ZA200802874A ZA200802874B ZA 200802874 B ZA200802874 B ZA 200802874B ZA 200802874 A ZA200802874 A ZA 200802874A ZA 200802874 A ZA200802874 A ZA 200802874A ZA 200802874 B ZA200802874 B ZA 200802874B
Authority
ZA
South Africa
Prior art keywords
lung diseases
guanylate cyclase
treating acute
chronic lung
soluble guanylate
Prior art date
Application number
ZA200802874A
Other languages
English (en)
Inventor
Krahn Thomas
Stasch Johannes-Peter
Weimann Gerrit
Thielemann Wolfgang
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ZA200802874B publication Critical patent/ZA200802874B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200802874A 2005-10-06 2008-04-02 Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases ZA200802874B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005047946A DE102005047946A1 (de) 2005-10-06 2005-10-06 Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten

Publications (1)

Publication Number Publication Date
ZA200802874B true ZA200802874B (en) 2009-09-30

Family

ID=37106347

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802874A ZA200802874B (en) 2005-10-06 2008-04-02 Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases

Country Status (13)

Country Link
US (1) US20090286781A1 (de)
EP (1) EP1945218A2 (de)
JP (1) JP2009510142A (de)
KR (1) KR20080065283A (de)
CN (1) CN101282727A (de)
AU (1) AU2006299149A1 (de)
BR (1) BRPI0616921A2 (de)
CA (1) CA2624716A1 (de)
DE (1) DE102005047946A1 (de)
IL (1) IL190619A0 (de)
RU (1) RU2417083C2 (de)
WO (1) WO2007039155A2 (de)
ZA (1) ZA200802874B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202008014557U1 (de) 2008-10-27 2009-03-12 Eberhard-Karls-Universität Tübingen Universitätsklinikum Therapeutische Verwendung
MY159697A (en) * 2010-02-05 2017-01-13 Adverio Pharma Gmbh Sgc stimulators or sgc activators alone and in combination with pde5 inhibitors for the treatment of cystic fibrosis
CA2803688A1 (en) * 2010-06-25 2011-12-29 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
CN102485724B (zh) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 取代噻吩基吡唑并吡啶类化合物及其医药用途
ES2583086T3 (es) * 2011-04-21 2016-09-19 Bayer Intellectual Property Gmbh Pirazolopiridinas sustituidas con fluoroalquilo y su uso
PT2875003T (pt) * 2012-07-20 2017-02-16 Bayer Pharma AG Novos ácidos 5-amino-tetra-hidroquinolina-2-carboxílicos e sua utilização
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
CN108785309A (zh) * 2018-04-23 2018-11-13 周静 化合物在制备治疗慢性肺病的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
CA2484089A1 (en) * 2002-04-26 2003-11-06 Altana Pharma Ag Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
GB2395431A (en) * 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
EP1675459A1 (de) * 2003-08-04 2006-07-05 Hemocorm Limited Verwendung von borancarbonaten für die therapeutische abgabe von kohlenmonoxid
EP1663239A4 (de) * 2003-09-10 2008-07-23 Cedars Sinai Medical Center Kaliumkanal-vermittelte zufuhr von mitteln durch die blut-hirn-schranke
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
US20050255178A1 (en) * 2004-02-04 2005-11-17 Bloch Kenneth D Enhancing the effectiveness of an inhaled therapeutic gas
EP1799210A1 (de) * 2004-10-05 2007-06-27 Bayer HealthCare AG Guanylatcyclasestimulator und stickoxid zur behandlung von bronchokonstriktion und pulmonaler vasokonstriktion

Also Published As

Publication number Publication date
RU2417083C2 (ru) 2011-04-27
AU2006299149A1 (en) 2007-04-12
WO2007039155A3 (de) 2007-10-11
CA2624716A1 (en) 2007-04-12
WO2007039155A2 (de) 2007-04-12
IL190619A0 (en) 2008-12-29
KR20080065283A (ko) 2008-07-11
EP1945218A2 (de) 2008-07-23
BRPI0616921A2 (pt) 2011-07-05
US20090286781A1 (en) 2009-11-19
CN101282727A (zh) 2008-10-08
JP2009510142A (ja) 2009-03-12
DE102005047946A1 (de) 2007-05-03
RU2008117303A (ru) 2009-11-20

Similar Documents

Publication Publication Date Title
IL190619A0 (en) Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases
IL188657A0 (en) Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
EP2007385A4 (de) Kardiovaskuläre zusammensetzung und ihre verwendung zur behandlung von morbus alzheimer
HK1112895A1 (en) 5-heteroaryl thiazoles and their use as pi3k inhibitors
ZA200610640B (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
ZA200802501B (en) Indenoisoquinolinone analogs and methods of use thereof
IL188031A0 (en) Use of thiazole derivatives and analogues in the treatment of cancer
EP2049554A4 (de) Synthetisches lungensurfaktant und seine verwendung
IL193693A0 (en) Purine compounds and methods of use thereof
HK1135099A1 (en) Aza-indolyl compounds and methods of use
PL1774356T3 (pl) Sposób oznaczania lipoprotein w płynach ustrojowych
EP2054386A4 (de) Non-flushing-niacinanaloga und verfahren zu deren anwendung
ZA200609141B (en) Compositions for Inhalation therapy and methods of use
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
EP2046122A4 (de) Hämoxygenase-hemmer und verfahren zu ihrer therapeutischen anwendung
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
ZA200804688B (en) Purine derivatives and methods of use thereof
PL1867241T3 (pl) Przyprawa mająca działanie polegające na nadawaniu zdecydowanego smaku
EP1837382A4 (de) Beschichtungswirkstoffzusammensetzung und ihre verwendung
PT1865966E (pt) Uso de fármacos anti-inflamatórios não esteróides por inalação no tratamento de bronquite aguda e crónica
ZA200800243B (en) Use of thiazole derivatives and analogues in the treatment of cancer
IL192031A0 (en) Use of cicletanine and other furopyridines for treatment of hypertension
HK1088228A1 (en) A chinese traditional medicine composition useful for the treatment of chronic prostatitis and the preparation of the same
EP1814553A4 (de) Gtpase-hemmer und deren verwendung zur regulierung von thrombozytenhyperaktivität